Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer

Rennes University Hospital100 enrolled

Overview

The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Stage IIIb and IV Non Small Cell Lung Cancer

Interventions

laboratory biomarker analysisOTHER

Next Generation SequencingOTHER

DNA AnalysisGENETIC

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed written informed consent * Male or female aged \>= 18 years * Stage IIIb and IV Non Small Cell Lung Cancer histologically confirmed Exclusion Criteria: * Tissue and plasma samples can not be provided for mutation analysis * Unwilling or unable to provide informed consent * Any serious medical condition that would interfere with the subject's safety

Locations (1)

CHU

Rennes, France

Outcomes

Primary Outcomes

Mutation profiling of circulating tumor DNA from plasma samples.

To evaluate the sensitivity of NGS to detect the genetic alterations in plasma tumor DNA.

Time frame: 1 year

Secondary Outcomes

Quantity of circulating tumor DNA in serially collected plasma specimens.

To evaluate the change of quantity of circulating tumor DNA during treatment.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.